Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones

被引:25
作者
Xiao, Zhu-Ping [1 ]
Li, Huan-Qiu [1 ]
Shi, Lei [1 ]
Lv, Peng-Cheng [1 ]
Song, Zhong-Cheng [1 ]
Zhua, Hai-Liang [1 ]
机构
[1] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China
关键词
3-aryl-1H-quinolin-4-ones; cytotoxicity; natural products; protein tyrosine kinases; structure-activity relationships;
D O I
10.1002/cmdc.200800057
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The antiproliferative activities of 36 3-aryl-1H-quinolin-4-ones were determined against two cancer cell lines (Hep G2 and KB) in vitro. The results indicate that most of these compounds show good cytotoxic activity against human cancer cell lines, but no cytotoxicity against a human normal cell line (L02). The positive control compounds genistein and 5-fluorouracil show no selectivity at inhibiting the growth of the above three cell lines. Generally, compounds that bear a halogen atom at the 8 position and a methoxy group at the 3' position exhibited remarkable cytotoxicity toward human cancer cell lines. Electron-withdra wing substituents at the 6 position decrease the antiproliferative activity significantly. We also put forward a pharmocophore model for 3-aryl-4-quinolinones binding with epidermal growth factor receptor protein tyrosine kinases (EGFR PTK). Out of the 36 synthetic compounds, 34 are reported for the first time.
引用
收藏
页码:1077 / 1082
页数:6
相关论文
共 26 条
[1]  
AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
[2]  
Al-Obeidi FA, 1998, BIOPOLYMERS, V47, P197, DOI 10.1002/(SICI)1097-0282(1998)47:3<197::AID-BIP2>3.0.CO
[3]  
2-H
[4]   Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model [J].
Conrad, Claudius ;
Ischenko, Ivan ;
Koehl, Gudrun ;
Wiegand, Ulrich ;
Guba, Markus ;
Yezhelyev, Maksim ;
Ryan, Anderson J. ;
Barge, Alan ;
Geissler, Edward K. ;
Wedge, Stephen R. ;
Jauch, Karl-Walter ;
Bruns, Christiane J. .
ANTI-CANCER DRUGS, 2007, 18 (05) :569-579
[5]  
Croisy M, 1997, HETEROCYCLES, V45, P683
[6]   Negative receptor signalling [J].
Dikic, I ;
Giordano, S .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :128-135
[7]   Protein tyrosine kinase inhibitors: new treatment modalities? [J].
Fabbro, D ;
Parkinson, D ;
Matter, A .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) :374-381
[8]   PICEATANNOL (3,4,3',5'-TETRAHYDROXY-TRANS-STILBENE) IS A NATURALLY-OCCURRING PROTEIN-TYROSINE KINASE INHIBITOR [J].
GEAHLEN, RL ;
MCLAUGHLIN, JL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (01) :241-245
[9]  
HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302
[10]   Synthesis and antiplatelet activity of phenyl quinolones [J].
Huang, LJ ;
Hsieh, MC ;
Teng, CM ;
Lee, KH ;
Kuo, SC .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (10) :1657-1662